Literature DB >> 34437680

EBV+ lymphoproliferative diseases: opportunities for leveraging EBV as a therapeutic target.

Keri Toner1,2,3,4, Catherine M Bollard1,3,4.   

Abstract

Epstein-Barr virus (EBV) is a ubiquitous human tumor virus, which contributes to the development of lymphoproliferative disease, most notably in patients with impaired immunity. EBV-associated lymphoproliferation is characterized by expression of latent EBV proteins and ranges in severity from a relatively benign proliferative response to aggressive malignant lymphomas. The presence of EBV can also serve as a unique target for directed therapies for the treatment of EBV lymphoproliferative diseases, including T cell-based immune therapies. In this review, we describe the EBV-associated lymphoproliferative diseases and particularly focus on the therapies that target EBV.
© 2022 by The American Society of Hematology.

Entities:  

Mesh：

Year:  2022        PMID： 34437680      PMCID： PMC8854679          DOI： 10.1182/blood.2020005466

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


  103 in total

1.  Constitutive AP-1 activity and EBV infection induce PD-L1 in Hodgkin lymphomas and posttransplant lymphoproliferative disorders: implications for targeted therapy.

Authors:  Michael R Green; Scott Rodig; Przemyslaw Juszczynski; Jing Ouyang; Papiya Sinha; Evan O'Donnell; Donna Neuberg; Margaret A Shipp
Journal:  Clin Cancer Res       Date:  2012-01-23       Impact factor: 12.531

Review 2.  Epstein-Barr virus lymphoproliferative disease after hematopoietic stem cell transplant.

Authors:  Rayne H Rouce; Chrystal U Louis; Helen E Heslop
Journal:  Curr Opin Hematol       Date:  2014-11       Impact factor: 3.284

3.  Off-the-shelf EBV-specific T cell immunotherapy for rituximab-refractory EBV-associated lymphoma following transplantation.

Authors:  Susan Prockop; Ekaterina Doubrovina; Stephanie Suser; Glenn Heller; Juliet Barker; Parastoo Dahi; Miguel A Perales; Esperanza Papadopoulos; Craig Sauter; Hugo Castro-Malaspina; Farid Boulad; Kevin J Curran; Sergio Giralt; Boglarka Gyurkocza; Katharine C Hsu; Ann Jakubowski; Alan M Hanash; Nancy A Kernan; Rachel Kobos; Guenther Koehne; Heather Landau; Doris Ponce; Barbara Spitzer; James W Young; Gerald Behr; Mark Dunphy; Sofia Haque; Julie Teruya-Feldstein; Maria Arcila; Christine Moung; Susan Hsu; Aisha Hasan; Richard J O'Reilly
Journal:  J Clin Invest       Date:  2020-02-03       Impact factor: 14.808

4.  Response to Rituximab Induction Is a Predictive Marker in B-Cell Post-Transplant Lymphoproliferative Disorder and Allows Successful Stratification Into Rituximab or R-CHOP Consolidation in an International, Prospective, Multicenter Phase II Trial.

Authors:  Ralf U Trappe; Daan Dierickx; Heiner Zimmermann; Franck Morschhauser; Peter Mollee; Jan M Zaucha; Martin H Dreyling; Ulrich Dührsen; Petra Reinke; Gregor Verhoef; Marion Subklewe; Andreas Hüttmann; Thomas Tousseyn; Gilles Salles; Volker Kliem; Ingeborg A Hauser; Corrado Tarella; Eric Van Den Neste; Olivier Gheysens; Ioannis Anagnostopoulos; Veronique Leblond; Hanno Riess; Sylvain Choquet
Journal:  J Clin Oncol       Date:  2016-12-19       Impact factor: 44.544

5.  Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation.

Authors:  Ann M Leen; Catherine M Bollard; Adam M Mendizabal; Elizabeth J Shpall; Paul Szabolcs; Joseph H Antin; Neena Kapoor; Sung-Yun Pai; Scott D Rowley; Partow Kebriaei; Bimalangshu R Dey; Bambi J Grilley; Adrian P Gee; Malcolm K Brenner; Cliona M Rooney; Helen E Heslop
Journal:  Blood       Date:  2013-04-22       Impact factor: 22.113

6.  Prospective phase II trial of extended treatment with rituximab in patients with B-cell post-transplant lymphoproliferative disease.

Authors:  Eva González-Barca; Eva Domingo-Domenech; Francisco Javier Capote; Jose Gómez-Codina; Antonio Salar; Alicia Bailen; Jose-María Ribera; Andres López; Javier Briones; Andres Muñoz; Maite Encuentra; Alberto Fernández de Sevilla
Journal:  Haematologica       Date:  2007-11       Impact factor: 9.941

Review 7.  Vaccine Development for Epstein-Barr Virus.

Authors:  Jeffrey I Cohen
Journal:  Adv Exp Med Biol       Date:  2018       Impact factor: 2.622

8.  Establishment and operation of a Good Manufacturing Practice-compliant allogeneic Epstein-Barr virus (EBV)-specific cytotoxic cell bank for the treatment of EBV-associated lymphoproliferative disease.

Authors:  Mark A Vickers; Gwen M Wilkie; Nicolas Robinson; Nadja Rivera; Tanzina Haque; Dorothy H Crawford; Jacqueline Barry; Neil Fraser; David M Turner; Victoria Robertson; Phil Dyer; Peter Flanagan; Helen R Newlands; John Campbell; Marc L Turner
Journal:  Br J Haematol       Date:  2014-07-26       Impact factor: 6.998

Review 9.  Rituximab in B-Cell Hematologic Malignancies: A Review of 20 Years of Clinical Experience.

Authors:  Gilles Salles; Martin Barrett; Robin Foà; Joerg Maurer; Susan O'Brien; Nancy Valente; Michael Wenger; David G Maloney
Journal:  Adv Ther       Date:  2017-10-05       Impact factor: 3.845

10.  CAR-T Cells Targeting Epstein-Barr Virus gp350 Validated in a Humanized Mouse Model of EBV Infection and Lymphoproliferative Disease.

Authors:  Constanze Slabik; Maja Kalbarczyk; Simon Danisch; Reinhard Zeidler; Frank Klawonn; Valery Volk; Nicole Krönke; Friedrich Feuerhake; Constanca Ferreira de Figueiredo; Rainer Blasczyk; Henning Olbrich; Sebastian J Theobald; Andreas Schneider; Arnold Ganser; Constantin von Kaisenberg; Stefan Lienenklaus; Andre Bleich; Wolfgang Hammerschmidt; Renata Stripecke
Journal:  Mol Ther Oncolytics       Date:  2020-08-08       Impact factor: 7.200
View more
  1 in total

1.  Impact of Tumour Epstein-Barr Virus Status on Clinical Outcome in Patients with Classical Hodgkin Lymphoma (cHL): A Review of the Literature and Analysis of a Clinical Trial Cohort of Children with cHL.

Authors:  Mahdi Nohtani; Katerina Vrzalikova; Maha Ibrahim; Judith E Powell; Éanna Fennell; Susan Morgan; Richard Grundy; Keith McCarthy; Sarah Dewberry; Jan Bouchal; Katerina Bouchalova; Pamela Kearns; Paul G Murray
Journal:  Cancers (Basel)       Date:  2022-09-01       Impact factor: 6.575
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.